Echoing this, BioNTech stock's Schaeffer's put/call open interest ratio (SOIR) of 1.14 sits higher than 98% of annual ...

In a report released today, Harry Gillis from Berenberg Bank upgraded BioNTech SE (BNTX – Research Report) to a Buy, with a price target of $130.00. The company’s shares closed yesterday at $101.87.

Berenberg initiated coverage of BioNTech (BNTX) with a Buy rating and $130 price target The firm says mRNA will revolutionize ...

BioNTech SE BNTX announced that it has entered into a definitive agreement to acquire China-based biotech, Biotheus, to ...

Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Buy rating on BioNTech SE (BNTX – Research Report). The associated ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...

BioNTech (NASDAQ:BNTX) said it has agreed to buy bispecific antibody developer Biotheus for up to $950M, including $150M in potential milestone payments. Under the deal, BioNTech (BNTX) will pay $800M ...

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.

Shares of BioNTech (BNTX) gained in pre-market trading after the company reported better-than-expected Q3 earnings. The biotech company’s earnings increased by 22.7% to €0.81 ($0.89 ...

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.